Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268280 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01268280: Clinical Trial Phase 2 study, sponsored by Cytokinetics.
NCT01268280 is a Phase 2 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01268280, a Phase 2 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
Primary Outcome
A quantitative motor assessment of muscular weakness on a scale of 0 to 3 with 0 representing "none" and 3 representing "severe". Muscular assessments included in the overall score are effects on double vision, ptosis, facial muscles, swallowing, speech, outstretched arms and legs, forced vital capacity, hand grip strength, and ability to lift head.
Interventions
- DRUG Placebo
- DRUG 500 mg CK-2017357
- DRUG 250 mg CK-2017357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Why NCT01268280 stopped before completion
NCT01268280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01268280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01268280 about?
NCT01268280 is a clinical study titled "Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis". The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
What is the current status of trial NCT01268280?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01268280?
The interventions under investigation include: Placebo (DRUG), 500 mg CK-2017357 (DRUG), 250 mg CK-2017357 (DRUG).
Who is sponsoring clinical trial NCT01268280?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01268280's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia